Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Akero Therapeutics Inc (NQ: AKRO )

22.02 -0.09 (-0.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 502,181
Open 22.18
Bid (Size) 21.60 (5)
Ask (Size) 22.50 (1)
Prev. Close 22.11
Today's Range 21.54 - 22.25
52wk Range 11.25 - 58.38
Shares Outstanding 50,086,978
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AKRO Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Against Akero Therapeutics, Inc.
From Robbins LLP
Via GlobeNewswire
ROSEN, A TOP RANKED LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal

Performance

YTD
-6.22%
-6.22%
1 Month
-4.80%
-4.80%
3 Month
+8.79%
+8.79%
6 Month
+52.60%
+52.60%
1 Year
-51.63%
-51.63%

More News

Read More
ROSEN, A TOP RANKED LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) Investors
From Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) Investors
From Law Offices of Howard G. Smith
Via Business Wire
AKRO INVESTOR ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Exscientia, and Akero and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Akero Therapeutics, Inc. (AKRO) Investors
From Kirby McInerney LLP
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Akero Therapeutics, Inc. (AKRO) Investor Notice: Robbins LLP Reminds Stockholders of the Akero Therapeutics, Inc. Class Action
From Robbins LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
AKRO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Akero Therapeutics, Inc. (AKRO) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Akero Therapeutics (AKRO) Slides After Failed Trial, Hit With Class Action Lawsuit – Hagens Berman
From Hagens Berman Sobol Shapiro LLP
Via GlobeNewswire
AKRO INVESTOR NOTICE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRO
From The Rosen Law Firm PA
Via GlobeNewswire
NASDAQ: AKRO: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Akero Therapeutics, Inc.
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
From Akero Therapeutics Inc.
Via GlobeNewswire
Stockholder Alert: Robbins LLP Informs Investors of the Class Action Filed Against Akero Therapeutics, Inc. (AKRO)
From Robbins LLP
Via GlobeNewswire
AKERO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Akero Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKRO
From Rosen Law Firm
Via Business Wire
AKRO INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc.with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.